Amlodipine And Benazepril Hydrochloride
NDC Package 42291-014-01

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Amlodipine And Benazepril Hydrochloride is do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes.Amlodipine and benazepril hydrochloride capsules  are contraindicated in patients with a history of angioedema, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules.Amlodipine and benazepril hydrochloride capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Marketed by Avkare, this product is identified by NDC 42291-014 and is authorized under FDA application ANDA202239.

Identification & Billing

NDC Package Code
42291-014-01
Package Description
100 CAPSULE in 1 BOTTLE
Product Code
42291-014
11-Digit Billing Format
42291001401
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk
  • RxCUI: 898342 - amLODIPine besylate 10 MG / benazepril HCl 20 MG Oral Capsule
  • RxCUI: 898342 - amlodipine 10 MG / benazepril hydrochloride 20 MG Oral Capsule
  • RxCUI: 898342 - amlodipine (as amlodipine besylate) 10 MG / benazepril hydrochloride 20 MG Oral Capsule
  • RxCUI: 898342 - Amlodipine 10 MG / BZP hydrochloride 20 MG Oral Capsule
  • RxCUI: 898346 - amLODIPine besylate 10 MG / benazepril HCl 40 MG Oral Capsule

Clinical Specifications

Proprietary Name
Amlodipine And Benazepril Hydrochloride
Dosage Form
-
Usage Information
Do not coadminister aliskiren with angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, including amlodipine and benazepril hydrochloride capsules in patients with diabetes.Amlodipine and benazepril hydrochloride capsules  are contraindicated in patients with a history of angioedema, with or without previous ACE inhibitor treatment, or patients who are hypersensitive to benazepril, to any other ACE inhibitor, to amlodipine, or to any of the excipients of amlodipine and benazepril hydrochloride capsules.Amlodipine and benazepril hydrochloride capsules are contraindicated in combination with a neprilysin inhibitor (e.g., sacubitril). Do not administer amlodipine and benazepril hydrochloride capsules within 36 hours of switching to or from a neprilysin inhibitor, e.g., sacubitril/valsartan [seeWarnings and Precautions (5.1)].

Regulatory & Marketing

Labeler Name
Avkare
FDA Application #
ANDA202239
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
06-20-2023
End Marketing Date
02-28-2026
Listing Expiration
02-28-2026
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 42291-014-01 identifies a specific commercial package of 100 capsule in 1 bottle of Amlodipine And Benazepril Hydrochloride, labeled by Avkare. This product is billed for "EA" each discreet unit and contains an estimated amount of 100 billable units per package. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Avkare on June 20, 2023. The current certification is valid through February 28, 2026.

How is this Avkare product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 42291001401. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
42291-014-01
11-Digit CMS (5-4-2)
42291-0014-01

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.